Table 3 Demographic and baseline characteristics of the trial subjects
Characteristics | Placebo (n = 58) | GC (n = 65) | UC-II (n = 63) |
|---|---|---|---|
Sex ((n) male + (n) female) | 28M + 30F | 28M + 37F | 33M + 30F |
Age (years) | 53.1 ± 1.02 | 52.6 ± 1.02 | 53.5 ± 0.99 |
Height (cm) | 162 ± 1.00 | 161 ± 1.12 | 161 ± 0.89 |
Body weight (kg) | 64.5 ± 1.20 | 66.0 ± 1.13 | 65.5 ± 1.12 |
Body mass index (kg/m2) | 24.7 ± 0.40 | 25.5 ± 0.40 | 25.2 ± 0.37 |
Kellgren Lawrence radiographic score | |||
Grade 2 (n) | 39 | 45 | 42 |
Grade 3 (n) | 19 | 20 | 21 |
Lequesne's Functional Index | 7.74 ± 0.12 | 8.02 ± 0.12 | 7.90 ± 0.13 |
Visual analog score (mm) | 58.2 ± 0.97 | 59.1 ± 0.97 | 58.4 ± 0.99 |
Total WOMAC score | 1382 ± 34.8 | 1396 ± 31.8 | 1398 ± 27.9 |
Mean WOMAC pain | 56.9 ± 1.36 | 57.5 ± 1.33 | 58.1 ± 1.03 |
Mean WOMAC physical function | 57.9 ± 1.51 | 58.5 ± 1.37 | 58.3 ± 1.24 |
Mean WOMAC stiffness | 56.3 ± 1.63 | 57.3 ± 1.52 | 58.1 ± 1.32 |
Knee flexion ROM (°) | 114 ± 1.62 | 114 ± 1.36 | 114 ± 1.57 |
Serum CRP (mg/L)a | 5.29 ± 1.47 | 8.15 ± 1.79 | 3.35 ± 0.58 |
Serum COMP (ng/mL)b | 325.2 ± 30.5 | 381.2 ± 44.1 | 334.6 ± 36.5 |
Synovial IL-6 (ng/mL)c | 13.3 ± 4.73 | 13.9 ± 5.57 | 15.3 ± 6.04 |
Synovial MMP-3 (μg/mL)d | 4.03 ± 1.20 | 2.54 ± 0.78 | 4.86 ± 1.74 |